Targeting the type 5 metabotropic glutamate receptor: a potential therapeutic strategy for neurodegenerative diseases?

Budgett, R. F., Bakker, G., Sergeev, E. , Bennett, K. A. and Bradley, S. J. (2022) Targeting the type 5 metabotropic glutamate receptor: a potential therapeutic strategy for neurodegenerative diseases? Frontiers in Pharmacology, 13, 893422. (doi: 10.3389/fphar.2022.893422)

[img] Text
271716.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

The type 5 metabotropic glutamate receptor, mGlu5, has been proposed as a potential therapeutic target for the treatment of several neurodegenerative diseases. In preclinical neurodegenerative disease models, novel allosteric modulators have been shown to improve cognitive performance and reduce disease-related pathology. A common pathological hallmark of neurodegenerative diseases is a chronic neuroinflammatory response, involving glial cells such as astrocytes and microglia. Since mGlu5 is expressed in astrocytes, targeting this receptor could provide a potential mechanism by which neuroinflammatory processes in neurodegenerative disease may be modulated. This review will discuss current evidence that highlights the potential of mGlu5 allosteric modulators to treat neurodegenerative diseases, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Furthermore, this review will explore the role of mGlu5 in neuroinflammatory responses, and the potential for this G protein-coupled receptor to modulate neuroinflammation.

Item Type:Articles
Additional Information:This research was funded by Medical Research Scotland.
Keywords:Pharmacology, GPCR, Alzheimer’s disease, neurodegenerative disease, neuroinflammation, G protein coupled receptors, drug discovery.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Bradley, Dr Sophie and Budgett, Rebecca and Sergeev, Miss Eugenia
Authors: Budgett, R. F., Bakker, G., Sergeev, E., Bennett, K. A., and Bradley, S. J.
College/School:College of Medical Veterinary and Life Sciences > School of Molecular Biosciences
College of Medical Veterinary and Life Sciences > School of Life Sciences
Journal Name:Frontiers in Pharmacology
Publisher:Frontiers Media
ISSN:1663-9812
ISSN (Online):1663-9812
Copyright Holders:Copyright © 2022 Budgett, Bakker, Sergeev, Bennett and Bradley
First Published:First published in Frontiers in Pharmacology 13: 893422
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record